Medical device marketing begins with a question no channel plan can answer: what is this device cleared or approved for, and who may be told about it. Promotion beyond the cleared indication is a regulatory problem rather than an aggressive marketing choice, and the boundary moves depending on whether the audience is a clinician, a hospital purchasing committee, a payer or a patient. An agency that opens with a funnel has started after the part that matters.
The cleared indication is the specification for every claim
Everything published has to sit inside what the device is cleared or approved for, and the language used to describe the benefit is part of that. This is not a constraint an agency can negotiate around with better copy. Settle the approved claim set with regulatory affairs before creative work starts, and build the assets so a single claim change does not invalidate the whole campaign.
The buying committee is several audiences with different permissions
A clinician, a purchasing committee, a hospital's value analysis team and a patient may each be addressed differently, and in some cases not at all. Map the audiences and what may be said to each before the plan, because the pages, the gating and even the site architecture follow from it. An agency that does not ask which audiences are in scope in the first conversation has not worked in the category.
Review cycles set the schedule, so build for them
Medical, legal and regulatory review determines the pace of everything, and agencies new to the sector plan as if approval were a formality. Ask how the agency structures work for review: modular claims with references attached, assets built so one comment does not restart the cycle, realistic lead times. A team that has done this will describe the process without being asked.
Clinical evidence is the content, and it is not marketing copy
The material that persuades clinicians is evidence: study design, endpoints, populations, limitations. Marketing that summarises a study selectively is both unpersuasive to the audience and a compliance risk. The useful agency work here is making genuine evidence findable and legible rather than making it sound better, which is a different skill and a rarer one.
Patient stories carry privacy obligations on top of claim ones
A patient's story or image is information about their care and requires written authorization rather than verbal agreement, and separately the FTC's endorsement guides require honest presentation of results that are not typical and disclosure of material connections. In a category where a single testimonial is persuasive, that combination is where the exposure concentrates.
Questions people ask about medtech marketing agency
Do we need an agency that specialises in medical devices?
Usually yes, because the review workflow, the claim discipline and the audience rules are learned rather than intuited, and a generalist can produce excellent work that cannot be approved. Test for it directly: ask how they would structure an asset so that one regulatory comment does not restart the whole review.
Can we market a device before clearance?
That is a regulatory question with real limits, and it is a question for your regulatory affairs function rather than for an agency. Any agency answering it confidently without asking about the device and its status has told you something useful about how it works.
Can we advertise to patients?
It depends on the device, the claim and the market, and where it is permitted it carries its own requirements. It is also a strategic question, since for many devices the decision is made by a clinician or a committee and patient-directed spend reaches people who cannot buy. Decide the audience question before the channel one.
What is the most common failure?
Creative built around a claim that regulatory will not approve, discovered after media is booked. It is entirely avoidable by settling the approved claim set first, and it happens constantly because claim approval feels like a delay at the point where the campaign feels urgent.